A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma Clinical Trial

Official title:
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal

Status Withdrawn

Clinical Trial Summary

The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anal Canal Squamous Cell Carcinoma
Carcinoma
Carcinoma, Squamous Cell

Clinical Trial Details

NCT number	NCT04499352
Study type	Interventional
Source	Boehringer Ingelheim
Contact
Status	Withdrawn
Phase	Phase 2
Start date	September 14, 2020
Completion date	October 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03690921` - Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial	Phase 2
Active, not recruiting	`NCT03712566` - Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
Active, not recruiting	`NCT02314169` - Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer	Phase 2
Recruiting	`NCT04166318` - Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study	Phase 2